Universe Pharmaceuticals (UPC) sets 2026 equity incentive plan with 84,500 shares
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Universe Pharmaceuticals INC adopted a new 2026 Equity Incentive Plan on April 14, 2026 to attract and retain employees, directors, and consultants and align their interests with shareholders.
The plan initially reserves up to 84,500 ordinary shares for awards and allows options, share appreciation rights, restricted shares, restricted share units, performance units, performance shares, and other share-based awards. From the first trading day in January 2027, the share pool may automatically increase each year by up to 10% of total ordinary shares issued and outstanding, subject to the Company’s authorized share capital and any lower amount set by the board. No director or officer can receive awards that would lift their holding above 75% of total voting power, and option terms may not exceed 10 years from the grant date.
Positive
- None.
Negative
- None.
Key Figures
Initial plan share reserve: 84,500 ordinary shares
Par value per share: US$0.00001 per share
Annual evergreen increase: 10% of ordinary shares
+4 more
7 metrics
Initial plan share reserve
84,500 ordinary shares
Maximum number of shares available for issuance under 2026 Equity Incentive Plan
Par value per share
US$0.00001 per share
Par value of ordinary shares eligible under the plan
Annual evergreen increase
10% of ordinary shares
Automatic increase each January starting 2027, based on issued and outstanding shares
Voting power cap
75% of voting power
Maximum combined voting power a director or officer may hold after awards
Maximum option term
10 years
Longest possible duration of any option granted under the plan
Plan adoption date
April 14, 2026
Date the 2026 Equity Incentive Plan was adopted by the Company
Evergreen start year
2027
First year the annual automatic share increase can occur
Key Terms
2026 Equity Incentive Plan, share appreciation rights, restricted share units, performance units, +2 more
6 terms
2026 Equity Incentive Plan financial
"adopted the Universe Pharmaceuticals INC 2026 Equity Incentive Plan"
performance units financial
"restricted share units, performance units, performance shares, and other share-based awards"
Performance units are company awards that become valuable only if specified business targets are met; they typically convert into shares or cash when performance goals are achieved. Think of them like a conditional bonus that turns into stock only if the company hits agreed milestones, so they align managers’ incentives with shareholders’ interests and can affect future share count, executive pay expense, and investor returns.
voting power financial
"shares representing in excess of 75% of the total combined voting power"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
FAQ
What did Universe Pharmaceuticals (UPC) approve in its April 2026 filing?
Universe Pharmaceuticals approved a 2026 Equity Incentive Plan on April 14, 2026. The plan is designed to attract and retain personnel, provide additional incentives, and better align employees’, directors’, and consultants’ interests with those of existing shareholders over the long term.
Who is eligible to participate in Universe Pharmaceuticals’ 2026 Equity Incentive Plan?
Eligible participants include employees, directors, and consultants of Universe Pharmaceuticals and its parents and subsidiaries. However, incentive share options under the plan may be granted only to employees of the Company or its parent or subsidiary entities, as specifically stated.
Are there ownership limits for directors and officers under the UPC 2026 plan?
Yes. No award may be granted if it would cause a director or officer to hold, directly or indirectly, shares representing more than 75% of the total combined voting power of all issued and outstanding shares, whether through grant, vesting, exercise, or settlement of that award.
What is the maximum term of options under the Universe Pharmaceuticals 2026 plan?
Each option granted under the 2026 Equity Incentive Plan may have a term of no more than 10 years from the grant date. This cap limits how long an option can remain exercisable, helping define the time horizon for potential share issuance from option exercises.